{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-416251","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-10-07T13:00:14+00:00","discovered_at":"2026-10-07T13:01:00.283621+00:00","generated_at":"2026-10-12T15:58:18.785941+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ultragenyx to sell FDA-awarded PRV for $210M cash; 20% of proceeds owed to NIH","bullets":["Asset purchase agreement signed Oct 6, 2026 to sell the Rare Pediatric Disease Priority Review Voucher awarded by FDA on Aug 19, 2026.","$210 million payable in cash to Ultragenyx at closing; no buyer named in the filing.","20% of gross proceeds (~$42M) payable to the NIH under a patent license agreement dated Dec 10, 2018.","PRV stemmed from FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), or DTX401, for glycogen storage disease type Ia in patients 8 and older.","Closing subject to customary conditions, including expiry or termination of the HSR waiting period; agreement to be filed with the FY2026 10-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-416251","json":"https://secwatch.observer/filing/0001193125-26-416251.json","markdown":"https://secwatch.observer/filing/0001193125-26-416251.md","text":"https://secwatch.observer/filing/0001193125-26-416251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/0001193125-26-416251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/rare-20261006.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:58:18.785941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}